Donor and patient characteristics according to transplantation arm
. | Bone marrow (n = 118) . | Peripheral blood (n = 109) . |
---|---|---|
Donor age, y | 44 (13-74) | 43 (17-67) |
Patient age, y | 44 (19-64) | 45 (19-64) |
CMV-seronegative patient and donor | 40 (34%) | 30 (28%) |
CML | 55 (47%) | 54 (49%) |
CP-1 | 49 (42%) | 46 (42%) |
> CP-1, AP | 6 (5%) | 8 (7%) |
AML | 43‡ (36%) | 39‡ (36%) |
CR-1 | 33 (28%) | 29 (27%) |
> CR-1 | 9 (8%) | 9 (8%) |
MDS | 20 (17%) | 16 (15%) |
Early disease* | 87 (74%) | 78 (72%) |
Advanced disease† | 31 (26%) | 31 (28%) |
. | Bone marrow (n = 118) . | Peripheral blood (n = 109) . |
---|---|---|
Donor age, y | 44 (13-74) | 43 (17-67) |
Patient age, y | 44 (19-64) | 45 (19-64) |
CMV-seronegative patient and donor | 40 (34%) | 30 (28%) |
CML | 55 (47%) | 54 (49%) |
CP-1 | 49 (42%) | 46 (42%) |
> CP-1, AP | 6 (5%) | 8 (7%) |
AML | 43‡ (36%) | 39‡ (36%) |
CR-1 | 33 (28%) | 29 (27%) |
> CR-1 | 9 (8%) | 9 (8%) |
MDS | 20 (17%) | 16 (15%) |
Early disease* | 87 (74%) | 78 (72%) |
Advanced disease† | 31 (26%) | 31 (28%) |
Data are presented as median (range) or n (%).
CP-1 indicates first chronic phase; AP, accelerated phase; and CR-1, first complete remission.
Early disease: AML CR-1, CML CP-1, refractory anemia, and refractory anemia with ringed sideroblasts.
Advanced disease: AML beyond CR-1, CML beyond CP-1 and AP, refractory anemia with excess blasts, and refractory anemia with excess blasts in transformation.
One patient with AML for whom disease status at transplantation was not known.